On November 5, 2025, Imexpharm was honored as one of the Top 40 companies recognized at the “Saigon Times CSR – Enterprises for the Community 2025” ceremony. With unwavering dedication to quality and integrity, Imexpharm has steadily built a CSR legacy spanning nearly half a century - one rooted in people and committed to community health.
Mr. Nguyen Dang Nam (center), Marketing Manager at Imexpharm, represents the company in receiving the “Saigon Times CSR – Enterprise for the Community 2025” recognition. Photo: Imexpharm.
With the theme “Toward a Sustainable Society”, the 7th annual Saigon Times CSR program, organized by Saigon Times Group, reaffirms that corporate social responsibility is inseparable from long-term sustainable development. The program emphasizes the importance of balanced development across three pillars: economic growth, environmental protection, and social equity.
These are also the pillars Imexpharm consistently practices — from advancing pharmaceutical manufacturing to EU-GMP standards, deeply investing in research and development (R&D), implementing ESG strategies, executing meaningful CSR initiatives, and cultivating a happy, people-centered workplace.
Building Value From a Mission to Protect Community Health
Guided by the mission “Providing high-efficacy healthcare solutions for the community,” Imexpharm remains committed to the vision “Trusted Quality – European Standards,” with a deeply human purpose: enabling people in Vietnam to access high-quality medicines, improving treatment outcomes, and easing financial burdens.
Mr. Nguyen Dang Nam (center), Marketing Manager at Imexpharm, represents the company in receiving the “Saigon Times CSR – Enterprise for the Community 2025” recognition. Photo: Imexpharm.
Stemming from this mission, Imexpharm prioritizes continuously strengthening international-standard manufacturing capabilities. The company currently leads the domestic pharmaceutical industry with 12 EU-GMP production lines across 3 manufacturing complexes.
Alongside manufacturing excellence, Imexpharm places strong emphasis on high-quality raw materials — rigorously assessed and strictly controlled, prioritizing clean, safe, CEP-certified inputs before registration and production approval by the Ministry of Health.
This commitment to quality is reinforced through a green and sustainable production model, including renewable energy use, greenhouse-gas reduction, modern energy-saving HVAC systems, and wastewater treatment meeting ISO 14001:2015 standards.
In response to Vietnam’s rising “double disease burden” — increasing infectious diseases alongside a surge in chronic conditions — Imexpharm continues to invest strongly in R&D. The company allocates 5% of annual revenue to R&D, manages 144 ongoing research projects, and launched 20 new products in the first 9 months of 2025, aiming to meet diverse clinical needs.
At the same time, Imexpharm accelerates global integration and technological advancement. Technology transfer with Genuone Sciences in 2024 and 28 European Marketing Authorizations (EU-MAs) mark key milestones, enabling Vietnam to progress toward independent production of high-value pharmaceuticals and global distribution.
Creating Value Through 5 Sustainable Pillars
Through nearly 50 years of development, Imexpharm has stayed committed to sustainable growth, with CSR at its core, anchored in five pillars: People, Environment, Prosperity, Collaboration, and Organizational Strength & Culture. People-centered responsibility remains at the heart of Imexpharm’s CSR.
People’s Doctor, Pharmacist Tran Thi Dao, General Director of Imexpharm, shared: "To make medicine is to do something good. For Imexpharm, CSR is not a side activity — it is the very pulse of our company, a persistent journey to uphold medical ethics and serve humanity. We believe community health is nurtured from sincere, modest acts: a high-quality tablet, a compassionate heart, a team that is valued and empowered. Every effort at Imexpharm - from EU-GMP-standard manufacturing to deep investment in R&D - is driven by one mission: to serve the health of the Vietnamese people and contribute to the sustainable development of society."
CSR is the cornerstone of Imexpharm’s sustainable development strategy, built on five pillars: People, Environment, Prosperity, Collaboration, and a strong, caring organizational culture. Photo: Imexpharm.
The IMEXFORUM 2025 scientific series held in Ho Chi Minh City, Da Nang, and Hanoi gathered leading respiratory experts, contributing to medical capacity building and promoting rational antibiotic use. The company also supports local communities through healthcare and educational initiatives.
In the face of global climate change — the defining challenge of the 21st century — Imexpharm recognizes environmental action as a duty. In March 2025, the company donated 500 trees to Da Lat City Youth Union, contributing to the city’s initiative to plant 3.8 million trees by 2025.
Finally, Imexpharm practices CSR within its own organization, fostering a caring, performance-driven environment. Understanding that great medicines are made by great people, the company builds talent on the foundation of “Expertise– Health– Resilience.”
In 2024, Imexpharm conducted 740 internal training programs, 88 external programs, and achieved 22,163 learning engagements, supported by a 360° feedback system for leadership development. Cultural cohesion is strengthened through sports, corporate events, volunteer programs, internal travel, and the annual Sales & Marketing Convention.